FGF21 exerts comparable pharmacological efficacy with Adalimumab in ameliorating collagen-induced rheumatoid arthritis by regulating systematic inflammatory response

Yu, Dan; Ye, Xianlong; Che, Ruixiang; Wu, Qiang; Qi, Jianying; Song, Lun; Guo, Xiaochen; Zhang, Shengqi; Wu, Huijun; Ren, Guangxin; Li, Deshan

doi:10.1016/j.biopha.2017.02.059

Cited by 17 publications

(8 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the authors reported that the anti-IL-1β treatment reduced the RA burden to a greater extent than the anti-TNF-α one, both clinically and histologically. Another study performing an in vivo TNF-α inhibition through adalimumab showed that the mRNA expression of IL-2 in the spleen of the treated mice was similar to the one of the healthy control group after daily subcutaneous injections of 1 mg/kg antibody [40]. Moreover, both the IL-1β and the TNF-α protein levels were reduced in the serum as well as in the spleens of the treated animals.…”

Section: Ra and Cytokines: A Tnf-α And Il-1β Crosstalk Modeled Both In Vitro And In Vivomentioning

confidence: 79%

Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds with One Stone as the Rationale of the 2LARTH® Micro-Immunotherapy Treatment

Jacques¹,

Floris²,

Lejeune³

2021

IJMS

View full text Add to dashboard Cite

Tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) are two cytokines involved in the perpetuation of the chronic inflammation state characterizing rheumatoid arthritis (RA). Significant advances in the treatment of this pathology have been made over the past ten years, partially through the development of anti-TNF and anti-IL-1 therapies. However, major side effects still persist and new alternative therapies should be considered. The formulation of the micro-immunotherapy medicine (MIM) 2LARTH® uses ultra-low doses (ULD) of TNF-α, IL-1β, and IL-2, in association with other immune factors, to gently restore the body’s homeostasis. The first part of this review aims at delineating the pivotal roles played by IL-1β and TNF-α in RA physiopathology, leading to the development of anti-TNF and anti-IL-1 therapeutic agents. In a second part, an emphasis will be made on explaining the rationale of using multiple therapeutic targets, including both IL-1β and TNF-α in 2LARTH® medicine. Particular attention will be paid to the ULD of those two main pro-inflammatory factors in order to counteract their overexpression through the lens of their molecular implication in RA pathogenesis.

show abstract

Section: Ra and Cytokines: A Tnf-α And Il-1β Crosstalk Modeled Both In Vitro And In Vivomentioning

confidence: 79%

Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds with One Stone as the Rationale of the 2LARTH® Micro-Immunotherapy Treatment

Jacques¹,

Floris²,

Lejeune³

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Akour et alalso described nesfatin activation by the endocrine growth factor FGF21 [270], which has been described as a new adipokine related to BMI in RA patients [271]. Association between FGF21 and rheumatic diseases would be of interest as FGF21 ameliorates CIA by regulating oxidative stress and inflammatory response [272,273]. In addition, FGF21, also inhibits macrophage-mediated inflammation [274] and down-regulates Th17-IL17 axis in CIA mice [275].…”

Section: Other Adipokines In Oa and Ramentioning

confidence: 99%

The Adipokine Network in Rheumatic Joint Diseases

Carrión

Frommer

Pérez‐García

et al. 2019

IJMS

134

View full text Add to dashboard Cite

Rheumatic diseases encompass a diverse group of chronic disorders that commonly affect musculoskeletal structures. Osteoarthritis (OA) and rheumatoid arthritis (RA) are the two most common, leading to considerable functional limitations and irreversible disability when patients are unsuccessfully treated. Although the specific causes of many rheumatic conditions remain unknown, it is generally accepted that immune mechanisms and/or uncontrolled inflammatory responses are involved in their etiology and symptomatology. In this regard, the bidirectional communication between neuroendocrine and immune system has been demonstrated to provide a homeostatic network that is involved in several pathological conditions. Adipokines represent a wide variety of bioactive, immune and inflammatory mediators mainly released by adipocytes that act as signal molecules in the neuroendocrine-immune interactions. Adipokines can also be synthesized by synoviocytes, osteoclasts, osteoblasts, chondrocytes and inflammatory cells in the joint microenvironment, showing potent modulatory properties on different effector cells in OA and RA pathogenesis. Effects of adiponectin, leptin, resistin and visfatin on local and systemic inflammation are broadly described. However, more recently, other adipokines, such as progranulin, chemerin, lipocalin-2, vaspin, omentin-1 and nesfatin, have been recognized to display immunomodulatory actions in rheumatic diseases. This review highlights the latest relevant findings on the role of the adipokine network in the pathophysiology of OA and RA.

show abstract

“…Earlier research on FGF21 function mainly focused on reducing blood sugar and lipids, lowering body weight, improving insulin resistance (IR), and cardiovascular diseases related to abnormal glucose and lipid metabolism, such as coronary heart disease, heart remodeling. 12 , 43 In recent years, the functions of FGF21 in inhibiting inflammation, reducing oxidative stress levels, 44 , 45 and inhibiting apoptosis of endothelial cells 46 and cardiomyocytes 47 have been studied. The regulatory effects of FGF21 on metabolic diseases, such as obesity, hyperlipidemia, and hyperglycemia, the damage repair effects on inflammation and apoptosis, and the blocking effects on some cancers indicate that FGF21 has a broad prospect for development.…”

Section: The Physiological Function Of Fgf21mentioning

confidence: 99%

Advances in Biological Functions and Clinical Studies of FGF21

Lin¹,

Zhang²,

Zhou³

et al. 2021

DMSO

View full text Add to dashboard Cite

Fibroblast growth factor 21 (FGF21) regulates many crucial biological processes in human and mammals, particularly metabolic modulation and protective effect after injury. Therefore, determining complex regulatory mechanisms and elucidating the signaling pathway may greatly promote the prevention, diagnosis, and treatment of related injury and metabolic diseases. This review focused on the metabolic modulation and protective effect of FGF21 and summarized the molecular mechanisms and clinical research developments.

show abstract

FGF21 exerts comparable pharmacological efficacy with Adalimumab in ameliorating collagen-induced rheumatoid arthritis by regulating systematic inflammatory response

Cited by 17 publications

References 65 publications

Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds with One Stone as the Rationale of the 2LARTH® Micro-Immunotherapy Treatment

Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds with One Stone as the Rationale of the 2LARTH® Micro-Immunotherapy Treatment

The Adipokine Network in Rheumatic Joint Diseases

Advances in Biological Functions and Clinical Studies of FGF21

Contact Info

Product

Resources

About